Welcome to GalapagosHealth


We have been working in inflammation for over 20 years and brought our first inflammation medicine to market in 2020. We are guided by the science and driven by the challenging to find new, innovative treatments for patients with chronic and debilitating conditions.  In our approach to combatting inflammatory diseases we have a commitment to match yours; to make a difference. While there are still unmet needs we bring an unstoppable resolve to be part of the solution.

This site has been developed as an information sharing and resource hub specifically for healthcare professionals. As you scroll through the pages you will find information about who Galapagos are, our work in inflammation and specifically Rheumatoid Arthritis and Inflammatory Bowel Diseases and science and innovation and product information.

Want to know more about unmet needs in RA, JAK-STAT, treatment guidelines, or clinical outcomes?
What causes JAK-STAT signalling dysregulation and inflammatory response?

Therapy Areas

Product Information

Please visit your country website for more detailed product information

Clinical Trials

Register now for access to information on ongoing clinical trials

Events

  • {{m.monthYear}}
No events found.
{{calendar.eventCategory}}

{{ calendar.eventHourMin}} ({{ calendar.timezone}})

{{calendar.eventName}}

{{calendar.eventDescription}}

  • {{page}}
No events found.
{{calendar.eventCategory}}

{{ calendar.eventHourMin}} ({{ calendar.timezone}})

{{calendar.eventName}}

{{calendar.eventDescription}}

  • {{page}}

About us

Our Research

Galapagos’ core research areas are inflammatory, fibrotic, and kidney diseases, where our clinical activity is focused across several indications.